Osivax Announces First Participant Vaccinated in Phase 2a Clinical Booster Trial of Influenza Vaccine Candidate OVX836 Phase 2a study to evaluate safety and immunogenicity of a booster dose of influenza vaccine candidate OVX836, three to five years after initial administration Enrollment of over 150 participants anticipated in Belgium Lyon, France – November 14, 2024 – Osivax, a biopharmaceutical …
Archives de l’auteur : Marianne Duparc
World Vaccines Congress Europe 2024
Barcelona, Spain – Oral PresentationNicola Groth, Chief Medical Officer, to provide a clinical update on OVX836 as part of a presentation entitled “Clinical Update of OVX836, a Novel Broad-Spectrum Type A Influenza Vaccine Candidate”.
Options XII for the Control of Influenza
Brisbane, Australia – Oral Presentation and PostersAlexandre Le Vert, Chief Executive Officer & Co-founder of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled “OVX836, A NP-Based Universal Influenza Vaccine Candidate, Triggers Effector CD4+ and Cytotoxic CD8+ T-Cells in Healthy Adults”. Delphine Guyon-Gellin, Chief of Business Development & Chief Operating …
Continuer la lecture « Options XII for the Control of Influenza »
Osivax and KM Biologics Enter Exclusive License Option Agreement for Broad-Spectrum “Universal” Influenza Vaccine in Japan
Osivax and KM Biologics Enter Exclusive License Option Agreement for Broad-Spectrum “Universal” Influenza Vaccine in Japan KM Biologics, a Meiji Group company, has received an exclusive option to exercise an exclusive license for the development, manufacturing and commercialization of Osivax’s broad-spectrum “universal” influenza vaccine candidates in Japan Osivax is to receive upfront payment for execution …
Osivax Completes Enrollment for Phase 1 Trial with Broad-Spectrum Sarbecovirus Vaccine Candidate, OVX033
Osivax completes Enrollment for Phase 1 Trial with Broad-Spectrum Sarbecovirus Vaccine Candidate, OVX033 48 healthy volunteers enrolled in first-in-human trial Topline data read-out expected by Q4 2024 Lyon, France – June 25, 2024 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced that it has completed …
ISIDORe User’s conference
Online – Oral PresentationCharlotte Primard, Non-Clinical Project Manager of Osivax, to provide an update on OVX033 as part of a presentation entitled “Immunogenicity, cross-reactivity and poly-functionality of immune responses induced by OVX033 with and without SQ for SARS-CoV-2”.
Influenza Vaccines for the World 2024
Siena, Italy – Oral PresentationNicola Groth, Chief Medical Officer of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled “Clinical development update on OVX836, a T-cell based broad-spectrum influenza vaccine”.
New influenza vaccine strategies aim to enhance protection with T-cell responses
Vaccine Developers Leverage mRNA and Other Powerful Technologies
World Congress Vaccine Washington 2024
Washington, DC – Oral PresentationAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled “Clinical development update on OVX836, a T-cell based broad-spectrum influenza vaccine”.